StoneX Group Inc. Takes Position in Kenvue Inc. (NYSE:KVUE)

StoneX Group Inc. purchased a new position in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,260 shares of the company’s stock, valued at approximately $433,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new stake in Kenvue during the 3rd quarter valued at $360,000. Benjamin Edwards Inc. bought a new stake in shares of Kenvue in the third quarter valued at about $1,323,000. Hilltop Holdings Inc. lifted its stake in Kenvue by 3.1% in the third quarter. Hilltop Holdings Inc. now owns 80,331 shares of the company’s stock worth $1,858,000 after acquiring an additional 2,434 shares during the period. Janus Henderson Group PLC grew its holdings in Kenvue by 40.6% during the 3rd quarter. Janus Henderson Group PLC now owns 219,576 shares of the company’s stock worth $5,080,000 after acquiring an additional 63,400 shares in the last quarter. Finally, Investment Management Corp of Ontario increased its position in Kenvue by 48.9% during the 3rd quarter. Investment Management Corp of Ontario now owns 63,627 shares of the company’s stock valued at $1,472,000 after purchasing an additional 20,900 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on KVUE shares. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Barclays lifted their price target on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Thursday, March 27th. Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $24.00.

Kenvue Price Performance

NYSE:KVUE opened at $23.87 on Thursday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The stock’s fifty day moving average is $22.50 and its two-hundred day moving average is $22.47. The company has a market capitalization of $45.62 billion, a P/E ratio of 45.04, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.